Blood Brain Barrier Technologies Market Size ($5,101.94Mn by 2028) Lead by Neurological Disorders (25.5% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
October 21, 2021 11:42 ET
|
The Insight Partners
New York, Oct. 21, 2021 (GLOBE NEWSWIRE) -- The new research study on the Blood Brain Barrier Technologies Market Size and Forecast to 2028 By Technology (Bispecific Antibody RMT Approach, Trojan...
Global Neuromodulation Devices Market to Undergo Significant Growth Due to Rising Adoption for Neuromodulation Devices in COVID-19 Pandemic – Exclusive Report [150 Pages] By Research Dive
August 25, 2021 09:02 ET
|
Research Dive
New York, USA, Aug. 25, 2021 (GLOBE NEWSWIRE) -- A latest report on the global neuromodulation devices market published by Research Dive sheds light on the impact of COVID-19 pandemic on the current...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 16, 2021 08:00 ET
|
Praxis Precision Medicines, Inc.
Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy...
Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders
June 22, 2021 08:30 ET
|
Neurona Therapeutics
Syndicate includes premier healthcare investors steeped in neurology Erica Whittaker, Ph.D., head of UCB Ventures, joins Neurona’s board of directors Latest financing brings total...
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)
June 16, 2021 08:00 ET
|
Neurona Therapeutics
Supporting data in preclinical model of drug-resistant epilepsy demonstrate seizure-freedom in 70% of the NRTX-1001 cell therapy treatment group versus 5% in the control group Data demonstrate...
Brain Scientific Receives Purchase Order and Begins Shipping Its Pediatric NeuroCap™ EEG Headsets
May 24, 2021 08:30 ET
|
Brain Scientific Inc.
NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific Inc. (OTCQB: BRSF) (the “Company”), a neurology-focused medical device and software company, today announces that...
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
April 30, 2021 09:00 ET
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Outlook on the Neurological Diseases Treatment Global Market to 2029 - Key Drivers, Challenges and Opportunities
April 29, 2021 07:18 ET
|
Research and Markets
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Neurological Diseases Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies...
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy
April 19, 2021 08:00 ET
|
Neurona Therapeutics
SAN FRANCISCO, April 19, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing neural cell therapies for the treatment of neurological disorders, today announced the...
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE
April 14, 2021 09:00 ET
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...